相似文献
1
Radiation Therapy in Non-Small-Cell Lung Cancer.
Cold Spring Harb Perspect Med. 2021 Oct 1;11(10):a037713. doi: 10.1101/cshperspect.a037713.
2
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Curr Treat Options Oncol. 2018 Jun 21;19(8):39. doi: 10.1007/s11864-018-0556-7.
3
A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).
Clin Lung Cancer. 2017 Jul;18(4):436-440.e1. doi: 10.1016/j.cllc.2017.01.007. Epub 2017 Jan 31.
4
A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
BMC Cancer. 2018 Nov 29;18(1):1183. doi: 10.1186/s12885-018-5039-5.
5
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Chest. 2013 May;143(5 Suppl):e278S-e313S. doi: 10.1378/chest.12-2359.
6
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Lancet Oncol. 2021 Jun;22(6):824-835. doi: 10.1016/S1470-2045(21)00149-2. Epub 2021 May 18.
7
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Radiother Oncol. 2019 May;134:44-49. doi: 10.1016/j.radonc.2019.01.027. Epub 2019 Feb 1.
8
Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Radiother Oncol. 2018 Sep;128(3):534-540. doi: 10.1016/j.radonc.2018.04.013. Epub 2018 Apr 26.
9
Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
Clin Lung Cancer. 2019 Jan;20(1):e53-e61. doi: 10.1016/j.cllc.2018.09.003. Epub 2018 Sep 8.
10
Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.
Lung Cancer. 2016 Dec;102:1-8. doi: 10.1016/j.lungcan.2016.10.002. Epub 2016 Oct 14.
引用本文的文献
1
Spread Through Air Spaces (STAS) as a Predictive and Prognostic Factor in Patients with Non-Small Cell Lung Cancer-Systematic Review.
Cancers (Basel). 2025 May 18;17(10):1696. doi: 10.3390/cancers17101696.
2
The Emerging Role and Mechanism of E2/E3 Hybrid Enzyme UBE2O in Human Diseases.
Biomedicines. 2025 Apr 29;13(5):1082. doi: 10.3390/biomedicines13051082.
3
Recombinant oncolytic virus NDV-anti-VEGFR2 enhances radiotherapy sensitivity in NSCLC by targeting VEGF signaling and impairing DNA repair.
Gene Ther. 2025 May 17. doi: 10.1038/s41434-025-00540-x.
4
DNA methylation-regulated HK1 overexpression contributes to irradiation-resistance by promoting glycolysis in non-small cell lung cancer.
Am J Cancer Res. 2024 Sep 15;14(9):4306-4319. doi: 10.62347/QMGJ2157. eCollection 2024.
5
Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing F-deoxyglucose positron emission tomography imaging.
BMC Cancer. 2024 Oct 5;24(1):1229. doi: 10.1186/s12885-024-13018-7.
6
Current status of immunotherapy for non-small cell lung cancer.
Front Pharmacol. 2022 Oct 13;13:989461. doi: 10.3389/fphar.2022.989461. eCollection 2022.
7
Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC.
J Oncol. 2022 Aug 30;2022:4714931. doi: 10.1155/2022/4714931. eCollection 2022.
8
The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma.
Front Oncol. 2022 Aug 23;12:991102. doi: 10.3389/fonc.2022.991102. eCollection 2022.
9
Elevated BTG2 improves the radiosensitivity of non-small cell lung cancer (NSCLC) through apoptosis.
Thorac Cancer. 2022 May;13(10):1441-1448. doi: 10.1111/1759-7714.14410. Epub 2022 Apr 7.
本文引用的文献
1
Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group.
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):455-461. doi: 10.1016/j.ijrobp.2020.03.015. Epub 2020 Apr 3.
2
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
Radiother Oncol. 2020 Mar;144:101-104. doi: 10.1016/j.radonc.2019.11.015. Epub 2019 Nov 28.
3
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.
4
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
J Thorac Oncol. 2019 Dec;14(12):2109-2119. doi: 10.1016/j.jtho.2019.07.025. Epub 2019 Aug 6.
5
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
JAMA Oncol. 2019 Sep 1;5(9):1283-1290. doi: 10.1001/jamaoncol.2019.1449.
6
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.
7
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Respir Investig. 2019 Sep;57(5):466-471. doi: 10.1016/j.resinv.2019.03.011. Epub 2019 May 16.
8
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.
9
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11.
10
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
J Clin Oncol. 2019 May 20;37(15):1316-1325. doi: 10.1200/JCO.18.00622. Epub 2019 Apr 3.
Zotero 插件